Argenta acquires manufacturing facility in Iowa, USA

July 2, 2015 – Argenta, a New Zealand owned pharmaceutical company dedicated to the health of animals, announced today it has acquired the manufacturing facility located at 141 Riverside Drive in Fort Dodge, Iowa, USA. Sitting on 6.2 hectares, the pharmaceutical facility is 13,500 square meters in area and comprises state of the art production space and several support laboratories. The subsidiary will be named AML Riverside and will be the third Argenta business operating out of the USA.

The seller is Boehringer Ingelheim Vetmedica, Inc. the fifth largest animal health pharmaceutical company in the United States. Terms of the deal were not disclosed.

Dr. Doug Cleverly, managing director and co-founder of Argenta said, "The purchase of the Riverside property continues our growth strategy in the US as well as New Zealand." Cleverly continued, "With our other US acquisitions we experienced a halo effect. Argenta's products and services offered from New Zealand have become more visible than ever before to our US clients. When we purchased a research company in New Jersey this led to increased demand for our chemistry research capability here in New Zealand."

Argenta, founded in 2006, is an innovation driven manufacturing operation headquartered in South Auckland. In 2008, Argenta acquired New Jersey based clinical contract research provider, AlcheraBio. Growth aspirations continued with Argenta opening two drug product research laboratories in Lawrence, Kansas City in 2011. Today, the New Zealand and US teams combined are 250 strong, working with 9 of the top 10 global animal health pharmaceutical companies as well as innovative startup firms, exporting products and services to over 50 countries including United States, Canada, Japan and Europe.

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…